Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ZVRA
Stock Latest News
Ratings
Zevra Therapeutics’ Strategic Advancements and Market Potential Drive Buy Rating
11d ago
ZVRA
Premium
Ratings
Zevra Therapeutics: Buy Rating Affirmed on European Market Expansion and Growth Potential
11d ago
ZVRA
Premium
The Fly
Zevra Therapeutics submits MAA to EMA for evaluation of arimoclomol
12d ago
ZVRA
Premium
The Fly
Zevra Therapeutics announces MIPLYFFA , OLPRUVA presentations at SERGG
22d ago
ZVRA
Premium
Ratings
Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases
22d ago
ZVRA
Premium
The Fly
Zevra Therapeutics announces publication of results on Phase 2/3 NPC-002
24d ago
ZVRA
Premium
The Fly
Zevra Therapeutics announces presentations on MIPLYFFA at NNPDF conference
28d ago
ZVRA
Premium
The Fly
Zevra Therapeutics price target raised to $29 from $25 at Cantor Fitzgerald
30d ago
ZVRA
Premium
The Fly
Zevra Therapeutics initiated with a Buy at H.C. Wainwright
1M ago
ZVRA
Premium
Company Announcements
Zevra Therapeutics Elects New Directors at Annual Meeting
2M ago
8K
ZVRA
Premium
The Fly
Zevra announces 3 proxy advisory firms recommended vote ‘FOR’ Dixon, Favorito
3M ago
ZVRA
Premium
Company Announcements
Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success
3M ago
ZVRA
Premium
Ratings
Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
3M ago
ZVRA
Premium
Ratings
Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating
3M ago
ZVRA
Premium
Ratings
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance
3M ago
ZVRA
Premium
The Fly
Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP
3M ago
ZVRA
Premium
Company Announcements
Zevra Therapeutics Reports Strong Q1 2025 Results
3M ago
ZVRA
Premium
The Fly
Zevra Therapeutics reports Q1 EPS (6c), consensus (18c)
3M ago
ZVRA
Premium
Pre-Earnings
ZVRA Upcoming Earnings Report: What to Expect?
3M ago
ZVRA
Premium
The Fly
Zevra Therapeutics urges stockholders to vote for director nominees
4M ago
ZVRA
Premium
The Fly
Zevra Therapeutics announces publication on arimoclomol
4M ago
ZVRA
Premium
The Fly
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
4M ago
ZVRA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
